Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.

ABSTRACT:

Introduction

Mutant BRAF is a driver oncogene found in 2% of lung adenocarcinomas and represents a target for therapy. We examined the clinical characteristics and course of patients with lung adenocarcinomas harboring BRAF mutations.

Methods

We identified patients with lung adenocarcinomas harboring BRAF mutations between 2009 and 2013 detected using a mass spectrometry-based polymerase chain reaction genotyping assay of hot-spot mutations involving codons corresponding to amino acids V600, D594, and G469 of BRAF. Patient characteristics and treatment outcomes were analyzed. Overall survival (OS) was compared with stage-matched patients with KRAS and EGFR mutant lung adenocarcinomas.

Results

Sixty-three patients were diagnosed with BRAF mutant lung adenocarcinomas be

SUBMITTER: Litvak AM 

PROVIDER: S-EPMC4251710 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature